[go: up one dir, main page]

EP1077704A4 - Combination therapy for treatment of depression - Google Patents

Combination therapy for treatment of depression

Info

Publication number
EP1077704A4
EP1077704A4 EP99921795A EP99921795A EP1077704A4 EP 1077704 A4 EP1077704 A4 EP 1077704A4 EP 99921795 A EP99921795 A EP 99921795A EP 99921795 A EP99921795 A EP 99921795A EP 1077704 A4 EP1077704 A4 EP 1077704A4
Authority
EP
European Patent Office
Prior art keywords
depression
treatment
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99921795A
Other languages
German (de)
French (fr)
Other versions
EP1077704A1 (en
Inventor
David Michelson
Gary Dennis Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1077704A1 publication Critical patent/EP1077704A1/en
Publication of EP1077704A4 publication Critical patent/EP1077704A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99921795A 1998-05-21 1999-05-10 Combination therapy for treatment of depression Withdrawn EP1077704A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8626898P 1998-05-21 1998-05-21
US86268P 1998-05-21
PCT/US1999/010092 WO1999059593A1 (en) 1998-05-21 1999-05-10 Combination therapy for treatment of depression

Publications (2)

Publication Number Publication Date
EP1077704A1 EP1077704A1 (en) 2001-02-28
EP1077704A4 true EP1077704A4 (en) 2002-01-30

Family

ID=22197424

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99921795A Withdrawn EP1077704A4 (en) 1998-05-21 1999-05-10 Combination therapy for treatment of depression

Country Status (5)

Country Link
EP (1) EP1077704A4 (en)
JP (1) JP2002515435A (en)
AU (1) AU3891299A (en)
CA (1) CA2332253A1 (en)
WO (1) WO1999059593A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
WO2000030648A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
JPWO2004014429A1 (en) * 2002-08-09 2005-12-02 三菱ウェルファーマ株式会社 Psychiatric disorder vulnerability control agent
JP2006506461A (en) * 2002-10-25 2006-02-23 コルジウム ファーマシューティカル， インコーポレイテッド Milnacipran pulsed release composition
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1575590B1 (en) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (en) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd COMBINATION OF CARBOSTIRILE DERIVATIVES AND INHIBITORS OF SEROTONINE REABSORTION FOR THE TREATMENT OF ANIMO DISORDERS
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
FR2851163B1 (en) * 2003-02-14 2007-04-27 USE OF DEXTROGYAN ENANTIOMER OF MILNACIPRAN FOR THE PREPARATION OF A MEDICINAL PRODUCT
EP1795196A3 (en) * 2003-04-04 2008-02-06 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
JP2006522144A (en) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド Treatment of lower urinary tract disorders
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James Combination therapy for dementia,depression and apathy
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (en) 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
AR062321A1 (en) 2006-08-25 2008-10-29 Boehringer Ingelheim Int CONTROLLED RELEASE SYSTEM AND METHOD TO MANUFACTURE
UY31335A1 (en) 2007-09-12 2009-04-30 VASOMOTOR SYMPTOMS TREATMENT
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
EP1094818A1 (en) * 1998-05-19 2001-05-02 Dalhousie University Use of tricyclic antidepressants for local analgesia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973594A (en) * 1986-12-17 1990-11-27 Glaxo Group Limited Medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
EP1094818A1 (en) * 1998-05-19 2001-05-02 Dalhousie University Use of tricyclic antidepressants for local analgesia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'SOUZA, D.L. ET AL.: "Effect of alosetron on the pharmacokinetics of fluoxetine", J CLIN PHARMACOL, vol. 41, 2001, pages 455 - 458, XP001034110 *
KORIECH, O.M.: "Fluoxetine treatment comprises the antiemetic efficacy of ondasetron in cancer patients", CLINICAL ONCOLOGY, vol. 7, 1995, pages 371 - 372, XP001034101 *
See also references of WO9959593A1 *

Also Published As

Publication number Publication date
AU3891299A (en) 1999-12-06
WO1999059593A1 (en) 1999-11-25
EP1077704A1 (en) 2001-02-28
CA2332253A1 (en) 1999-11-25
JP2002515435A (en) 2002-05-28

Similar Documents

Publication Publication Date Title
EP1077704A4 (en) Combination therapy for treatment of depression
GB9824436D0 (en) Methods of treatment
EP1063990A4 (en) Therapy of estrogen-associated disorders
IL139591A0 (en) Combination therapy for treatment of bipolar disorders
IL139592A0 (en) Combination therapy for treatment of refractory depression
PL348107A1 (en) Therapy for improving cognition
HU0002509D0 (en) Combination therapy for treatment of migraine
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
HUP0100365A3 (en) Combination therapy for the treatment of aids
HU0002508D0 (en) Combination therapy for treatment of migraine
IL136025A0 (en) Combination therapy for the treatment of migraine
GB9819999D0 (en) Treatment of cancer
GB2343629B (en) Treatment of cellulite
GB0020261D0 (en) Therapeutic treatment
IL136024A0 (en) Combination therapy for the treatment of migraine
GB9704174D0 (en) Agent for medical treatment
IL120955A0 (en) Treatment of osteoporosis
PL346528A1 (en) Treatment of depression
ZA9810306B (en) Combination therapy for the treatment of aids
GB9721978D0 (en) Treatment of depression
GB9807938D0 (en) Combination therapy for the treatment of AIDS
GB9819590D0 (en) Combination therapy for the treatment of aids
SI1068199T1 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
ZA982994B (en) Therapeutic treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001120;LT PAYMENT 20001120;LV PAYMENT 20001120;RO PAYMENT 20001120;SI PAYMENT 20001120

A4 Supplementary search report drawn up and despatched

Effective date: 20011218

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/55 A, 7A 61K 31/44 B, 7A 61K 31/415 B, 7A 61K 31/445 B, 7A 61K 31/34 B, 7A 61K 31/15 B, 7A 61K 31/135 B, 7A 61K 31/38 B, 7A 61K 31/55 J, 7A 61K 31:135 J, 7A 61K 31:38 J, 7A 61K 31:445 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020302

R18D Application deemed to be withdrawn (corrected)

Effective date: 20020301